Liang Tie-Jun, Liu Hui, Zhao Xiao-Qian, Tan Yan-Rong, Jing Kai, Qin Cheng-Yong
Department of Digestive Diseases, Provincial Hospital Affiliated to Shandong University, No. 219, Jing Wu Road, Huai Yin District, Jinan, Shandong Province, 250021, People's Republic of China.
Tumour Biol. 2014 Jan;35(1):339-43. doi: 10.1007/s13277-013-1046-y. Epub 2013 Sep 8.
Methylenetetrahydrofolate reductase (MTHFR) is one of the most important enzymes for folate metabolism which plays a key role in cell metabolism. MTHFR rs1801131 (A1298C) polymorphism can decrease in vitro MTHFR enzyme activity and has been hypothesized to be associated with liver cancer risk. This study aimed to quantify the strength of the association between MTHFR rs1801131 polymorphism and liver cancer risk by performing a meta-analysis. We searched the PubMed and Wanfang databases for studies relating on the association between MTHFR rs1801131 polymorphism and risk of liver cancer. Seven studies with 2,030 cases of liver cancer and 3,096 controls were finally included into the meta-analysis. Meta-analysis of a total of seven studies showed that the homozygote genotype CC of MTHFR rs1801131 polymorphism was significantly associated with decreased risk of liver cancer (for CC versus AA: odds ratio (OR) = 0.65, 95% confidence interval (CI) 0.47-0.89, P = 0.007; for CC versus AA + AC: OR = 0.65, 95% CI 0.48-0.89, P = 0.006). Subgroup by race showed that the homozygote genotype CC of MTHFR rs1801131 polymorphism was significantly associated with decreased risk of liver cancer in Asians (CC versus AA: OR = 0.64, 95% CI 0.46-0.90, P = 0.010; for CC versus AA + AC: OR = 0.63, 95% CI 0.45-0.88, P = 0.007). However, the association in Caucasians was still unclear owing to the limited data available now. Thus, Asian individuals with the homozygote genotype CC of MTHFR rs1801131 polymorphism are significantly associated with decreased risk of liver cancer. The association in Caucasians needs further studies.
亚甲基四氢叶酸还原酶（MTHFR）是叶酸代谢中最重要的酶之一，在细胞代谢中起关键作用。MTHFR rs1801131（A1298C）多态性可降低体外MTHFR酶活性，据推测与肝癌风险相关。本研究旨在通过进行荟萃分析来量化MTHFR rs1801131多态性与肝癌风险之间关联的强度。我们在PubMed和万方数据库中搜索了有关MTHFR rs1801131多态性与肝癌风险关联的研究。最终，七项研究（共2030例肝癌病例和3096例对照）被纳入荟萃分析。对总共七项研究的荟萃分析表明，MTHFR rs1801131多态性的纯合子基因型CC与肝癌风险降低显著相关（CC与AA比较：比值比（OR）=0.65，95%置信区间（CI）0.47 - 0.89，P = 0.007；CC与AA + AC比较：OR = 0.65，95% CI 0.48 - 0.89，P = 0.006）。按种族进行的亚组分析表明，MTHFR rs1801131多态性的纯合子基因型CC与亚洲人肝癌风险降低显著相关（CC与AA比较：OR = 0.64，95% CI 0.46 - 0.90，P = 0.010；CC与AA + AC比较：OR = 0.63，95% CI 0.45 - 0.88，P = 0.007）。然而，由于目前可用数据有限，白种人中的关联仍不明确。因此，MTHFR rs1801131多态性纯合子基因型CC的亚洲个体与肝癌风险降低显著相关。白种人中的关联需要进一步研究。
